

NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

17 May 2021 (#13)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or <a href="www.grants.nih.

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PA-21-180 Type: R34

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. Aids dates: September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.

Budget: Direct costs are limited to \$450,000 over the 3-year project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted may not exceed three years.

2. Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PA-21-205 Type: R34

Application Due Date: Aids dates: September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. "Intervention" here may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition or transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

Budget: Direct costs are limited to \$450,000 over a three-year period, with no more than \$225,000 in direct costs allowed in any single year. The maximum period is 3 years.

3. Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PA-21-219

Type: R21

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. Aids dates: September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing "mechanistic clinical trials or studies" (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description.

Budget: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is two years.

4. NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: PA-21-235 Type: R21

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. Aids dates: September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is two years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: Christa
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University

2038 Wilcocks Building, Ryneveld Street Enquiries: *Lizél*

e: <u>lizelk@sun.ac.za</u> | t: +27 21 808 2105